Royalty Report: Drugs, Personal Care Products, Pharmaceuticals – Collection: 5774

$100.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Drugs
  • Personal Care Products
  • Pharmaceuticals
  • Cancer

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 5774

License Grant
The Denmark company hereby grants an exclusive license  with the right under the Trademark, Patents and Technical Information owned by, or licensed to, the Licensor to import, store, distribute, use, sell and offer to sell the Products in the fifty states of the United States of America, the District of Columbia, its territories and current possessions.
License Property
Combination Product shall mean the pharmaceutical formulations containing both the Compound and Betamethasone Dipropionate in an ointment. Compound shall mean the compound Calcipotriene, a vitamin D analogue with the formula C27H4003.

Leo Product Branding shall mean the Trademark, the Leo name, the Assyrian Lion, the Leo Logo Guidelines, the Leo Product Concept, and any domain names or websites related to the Product in the Territory.

Field of Use
The Parties to the Agreement wish to explore certain opportunities in relation to topical treatment and prevention of psoriasis with calcipotriol (calcipotriene) alone or in combination with steroids.

IPSCIO Record ID: 7701

License Grant
Licensor of Denmark hereby grants Irish Licensee an exclusive license with the right to sublicense Licensee's Affiliates, under the Trademark, Patents and Technical Information owned by, or licensed to, Licensor to import, store, distribute, use and sell the Products in the Territory.
License Property
The trademark Dovonex(R) is owned by the Licensor.

Dovonex(R) Product shall mean products containing the Compound and sold under the trademark Dovonex(R) in the Territory.

'Combination Product' shall mean the pharmaceutical formulations containing both the Compound and Betamethasone Dipropionate in an ointment.

Compound shall mean the compound Calcipotriene, a vitamin D analogue with the formula C27H4003.

Dovonex® (calcipotriene cream) Cream, 0.005% contains calcipotriene monohydrate, a synthetic vitamin D3 derivative, for topical dermatological use. Calcipotriene is a form of synthetic vitamin D3 that is formulated to slow skin cell growth, flatten lesions and remove scale. It also can be used to treat psoriasis on the scalp and nails.

IPSCIO Record ID: 266775

License Grant
For Exclusivity, the Licensor of Denmark grants an exclusive license to and under the Patent Rights, Regulatory Information and Know-how to make, have made, use, lease, sell, and/or import the Product in the Field, in the Territory; and to sublicense to third parties the rights granted.

For Exclusivity to Epi-Seocalcitol, the Licensor of Denmark grants an exclusive license to the rights pertaining to Epi-Seocalcitol under the Patent Rights, Regulatory Information and Know-how to make, have made, use, lease, sell, and/or import the Product in the Field, in the Territory; and to sublicense to third parties the rights granted.

License Property
Licensor is the sole owner of Patent Rights, Know-how and Regulatory Information relating to Seocalcitol,  a synthetic vitamin D analog, believed that it can be used in combination with chemotherapy for prostate cancer patients.

Seocalcitol shall mean the active substance known under the chemical name 1(S),3(R)-dihydroxy-20(R)-(5’-ethyl-5’-hydroxy-hepta-1’(E), 3’(E) – dien-1’-yl)-9,10-secopregna-5(Z),7(E),10(19)-triene, which is an analogue of vitamin D.

Epi-Seocalcitol shall mean the active substance known under the chemical name 1(S),3(R)-dihydroxy-20(S)-(5’-ethyl-5’-hydroxy-hepta-1’(E), 3’(E) – dien-1’-yl)-9,10-secopregna-5(Z),7(E),10(19)-triene, which is an analogue of vitamin D.

Field of Use
Field of Use shall mean all uses.  Licensee is a biopharmaceutical company that in-licenses novel therapeutics and develops such therapeutics for the treatment of cancer.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.